Pre-Procedural Markers for AF Ablation

Risk Stratification and Outcome Prediction

• The European Society of Cardiology recommends using the CHA₂DS₂-VASc score to predict thromboembolic risk and long-term outcomes after AF ablation, with a score of 0-1 indicating lower risk, 2-4 indicating intermediate risk, and ≥5 indicating high risk 2
• The CHA₂DS₂-VASc score includes factors such as congestive heart failure, hypertension, age, diabetes, prior stroke/TIA, vascular disease, and female sex, with corresponding point values 1

Calculation and Interpretation

• The CHA₂DS₂-VASc score can be used to determine the risk of AF recurrence and major adverse cardiovascular events, with higher scores indicating increased risk 1
• A score of ≥2 in males or ≥3 in females indicates a high risk of thromboembolic events and warrants indefinite anticoagulation 3

Anticoagulation Decisions

• The European Society of Cardiology recommends at least 2 months of anticoagulation post-ablation, regardless of CHA₂DS₂-VASc score or rhythm outcome 2
• Pre-procedural anticoagulation for at least 3 weeks is required before ablation in patients at elevated thromboembolic risk 2

Additional Pre-Procedural Markers

• Cardiac imaging findings, such as left atrial size and left atrial appendage emptying velocity, can provide additional information on thromboembolic risk 1
• Biomarkers, such as high-sensitivity cardiac troponin T/I and NT-proBNP, can add prognostic value in low-intermediate risk patients 1
• AF pattern considerations, such as paroxysmal or permanent AF, can influence thromboembolic risk 1

Common Pitfalls to Avoid

• The European Society of Cardiology recommends against performing AF ablation solely to eliminate anticoagulation, as this approach increases stroke risk 3
• Transesophageal echocardiography is essential before left atrial ablations to exclude intracardiac thrombi in at-risk patients 6